In Focus channel feed

No longer ‘dead or just hi­ber­nat­ing,’ drug­mak­ers re­turn to heart med­i­cines

8 months ago
R&D

Rare dis­ease tri­als can't find enough pa­tients. It's forc­ing the FDA to re­think its ap­proach

9 months ago
FDA+

‘Hard­er to find homes’: Lat­est wave of biotech lay­offs could test the in­dus­try

9 months ago
People

A ra­dioac­tive prostate can­cer ther­a­py is a last life­line for pa­tients. No­var­tis can't make enough of it

9 months ago
R&D

Decades af­ter break­through, sci­en­tists still puz­zling over mR­NA de­liv­ery

9 months ago
R&D

Thou­sands of gene and cell ther­a­pies are in­un­dat­ing FDA re­view­ers as the agency tries to keep up

9 months ago
Pharma
Cell/Gene Tx

How Pur­due's $272M ad­dic­tion pay­out fund­ed a new home for its dis­card­ed non-opi­oid re­search

9 months ago
Pharma

A stem cell pi­o­neer sent an ex­per­i­ment in­to space. Pa­tients are the next fron­tier

10 months ago
People
Cell/Gene Tx

The con­fer­ence is back. What about the in­dus­try? Tak­ing the biotech pulse at #JPM23

10 months ago
Financing

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls

Last year
R&D

Covid-19 spurred a his­toric vac­cine R&D ef­fort. What does it mean for fu­ture pan­demics?

Last year
R&D
Coronavirus

A biotech paused a gene ther­a­py hatched by fam­i­lies. Now they want con­trol

Last year
Cell/Gene Tx

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Last year
People
Pharma

Even as pan­dem­ic re­cedes, short-staffed tri­al sites leave can­cer pa­tients wait­ing

Last year
R&D
Pharma

Chi­na's DNA gi­ant con­fronts skep­ti­cism in US ex­pan­sion bid

Last year
China
Diagnostics

Af­ter years of fail­ures, the hunt for a new type of Parkin­son’s drug is on

Last year
R&D

Biotech's 'sug­ar high' led to a cor­rec­tion, but win­ter dol­drums could make way for a turn­around sto­ry this fall

Last year
Financing

Biotech’s down­turn fu­els a bil­lion­aire’s niche in­vest­ment in­dus­try

Last year
R&D

Those big bil­lion-dol­lar PhI­II stud­ies? Mar­tin Lan­dray says they can be done for a tiny frac­tion of the cost

Last year
R&D

Why non-opi­oid pain drugs keep fail­ing — and what's next for the field

Last year
R&D

An MIT pro­fes­sor's rare dis­ease quest rip­ples through­out biotech

Last year
People

Af­ter Roe, star­tups seek to fill Big Phar­ma’s male con­tra­cep­tion gap

Last year
Startups

Af­ter abor­tion rul­ing, biotechs be­hind nov­el con­tra­cep­tives say tide is turn­ing on in­sur­ance cov­er­age

Last year

DNA se­quenc­ing gi­ant Il­lu­mi­na bat­tles an­titrust reg­u­la­tors and grow­ing com­pe­ti­tion

Last year
Pharma
First page Previous page 12345 Next page Last page
A service from the Financial Times